Ranbaxy Gains FDA Approval To Market Amoxicillin And Clavulanate Potassium For Oral Suspension USP

... Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to market Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 600 mg/42.9 mg (base) / 5 mL. [click link for full article] ...